Preclinical studies on KIR-SOCS1 peptidomimetics have demonstrated efficacy in suppressing lymphocyte activation and reducing lupus pathology, potentially complementing current JAK inhibitor strategies (42–44). Here, SOCS1 is linked to systemic lupus erythematosus.